Efficacy of temozolomide combined with whole brain radiotherapy in the treatment of non-small cell lungcancer brain metastases
替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移瘤的疗效观察

摘要

目的 分析在非小细胞肺癌转移瘤的治疗中采用替莫唑胺联合全脑放疗的效果。方法 选取2022年9月至2023年9月本院收治的非小细胞肺癌转移瘤患者平均分为两组，共计90例即分为替莫唑胺联合全脑放疗的研究组（n=45）和全脑放疗的参照组（n=45），统计结果比较。结果 研究组患者治疗后的疾病缓解率和控制率均高于参照组，治疗后无论是肿瘤标志物含量还是免疫功能均优于参照组（P＜0.05）。结论 在非小细胞肺癌脑转移瘤的治疗中采用替莫唑胺联合全脑放疗具有一定的效果，不仅能够降低患者的免疫功能损伤情况，还能使肿瘤标志物含量降低。

Abstract

Objective To analyse the effect of using temozolomide combined with whole brain radiotherapy in the treatment of non-small cell lung cancer metastases.
Methods Non-small cell lung cancer metastatic tumour patients admitted to our hospital from September 2022 to September 2023 were selected and divided into two groups on average, a total of 90 cases i.e., divided into the study group of temozolomide combined with whole-brain radiotherapy (n=45) and the reference group of whole-brain radiotherapy (n=45), and the statistical results were compared.
Results The disease remission rate and control rate of the patients in the study group were higher than those in the reference group, and both the tumour marker content and immune function were better than those in the reference group after treatment (P < 0.05).
Conclusion   The use of temozolomide combined with whole-brain radiotherapy in the treatment of non-small cell lung cancer brain metastases has a certain effect, which can not only reduce the impairment of immune function of the patients, but also reduce the content of tumour markers.